Anticancer Properties of Marine Peptides/Toxins Using Zebrafish Model

  • Saravanan Ramachandran
  • Senthilkumar Rajagopal


The biological diversity of the marine atmosphere is immense and therefore is an astonishing resource for the anticancer and new drug discovery. Modern technological and methodological developments in isolation, purification and structure elucidation of toxins and cyclic peptides have been evaluated for various novel anticancer screening. In this chapter, the cytotoxicity of the PSG toxin against breast cancer cell lines is examined using the MTT assay. The PSG toxin of selected cuttlefish exhibits highest cytotoxicity against the MCF-7 breast cancer cells (IC50–10.64 μM). Zebrafish xenograft is the topmost model for drug screening in the arena of cancer research and preclinical study. The zebrafish xenotransplantation model is a distinctive and less cost-effective tool for the investigation of cancer cell biology.


Marine toxins Peptides Breast cancer MTT assay Zebrafish 



The author gratefully acknowledges the Department of Biotechnology, Ministry of Science and Technology, Government of India (BT/PR15676/AAQ/03/794/2016).


  1. American Cancer Society (2016) Cancer facts and figures 2016. American Cancer Society, AtlantaGoogle Scholar
  2. Anderson BO, Jakesz R (2008) Breast cancer issues in developing countries: an overview of the breast health global initiative. World J Surg 32(12):2578–2585CrossRefGoogle Scholar
  3. Aneiros A, Garateix A (2004) Bioactive peptides from marine sources: pharmacological properties and isolation procedures. J Chromatogr B803:41–53Google Scholar
  4. Asolkar RN, Freel KC, Jensen PR, Fenical W, Kondratyuk TP, Park EJ, Pezzuto JM (2009) Arenamides, cytotoxic NF-kappa B inhibitors from the marine actinomycete Salinisporaarenicola. J Nat Prod 72:396–402CrossRefGoogle Scholar
  5. Beesoo R, Neergheen-Bhujun V, Bhagooli R, Bahorun T (2014) Apoptosis inducing lead compounds isolated from marine organisms of potential relevance in cancer treatment. Mut Res 768:84–97CrossRefGoogle Scholar
  6. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, Incalci MD (2003) Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1(flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17:52–59CrossRefGoogle Scholar
  7. Cao Z, Gerwick WH, Murray TF (2010) Antillatoxin is a sodium channel activator that displays unique efficacy in heterologously expressed rNav1.2, rNav1.4 and rNav1.5 alpha subunits. BMCNeuroscience 11:154–166Google Scholar
  8. Corrao MA, Guindon GE, Sharma N, Shokoohi DF (2000) Tobacco control country profiles. American Cancer Society, AtlantaGoogle Scholar
  9. Cueto M, Jensen PR, Fenical M (2000) N-methylsansalvamide, a cytotoxic cyclic depsipeptide from a marine fungus of the genus Fusarium. Phytochemistry 55(3):223–226CrossRefGoogle Scholar
  10. Davidson SK, Allen SW, Lim GE, Anderson CM, Haygood MG (2001) Evidence for the biosynthesis of bryostatins by the bacterial symbiotic Candidates Endobugulasertula of the Bryozoan Bugulaneritina. Appl Environ Microbiol 67(10):4531–4537CrossRefGoogle Scholar
  11. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev 24(10):1495–1506CrossRefGoogle Scholar
  12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefGoogle Scholar
  13. IARC Hand Books of Cancer Prevention (2005) International Agency for Research on Cancer. WHO, IARC PressGoogle Scholar
  14. International Agency for Research on Cancer (IARC) (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC Press, LyonGoogle Scholar
  15. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G (2005) Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol 68(2):502–510PubMedGoogle Scholar
  16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer J Clin 61:69–90Google Scholar
  17. Lee HS, Phat C, Choi SU, Lee C (2013) Synergistic effect of a novel cyclic pentadepsipeptide, neon-methylsansalvamide, and paclitaxel on human multidrug resistance cancer cell lines. Anti-Cancer Drug 24(5):455–460CrossRefGoogle Scholar
  18. Lovera GC, Rios VAJ, Guerra-Varela J, Sanchez L, de-la Fuente M (2017) The potential of Zebrafish as a model organism for improving the translation of genetic anticancer nanomedicines. Genes 8(349):2–20Google Scholar
  19. Mudit M, El Sayed KA (2016) Cancer control potential of marine natural product scaffolds through inhibition of tumor cell migration and invasion. Drug Discov Today 21:1745–1760CrossRefGoogle Scholar
  20. Mullard A (2015) FDA approves first immunotherapy combo. Nat Rev Drug Discov 14:739Google Scholar
  21. Newman DJ, Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 79(3):629–661CrossRefGoogle Scholar
  22. Ngo DH, Vo TS, Ngo DN, Wijesekara I, Kim SW (2012) Biological activities and potential health benefits of bioactive peptides derived from marine organisms. Int J Biol Macromol 51:378–383CrossRefGoogle Scholar
  23. Nicolini A, Carpi A, Ferrari P, Biava PM, Rossi G (2016) Immunotherapy and hormone-therapy in metastatic breast cancer: a review and an update. Curr Drug Targets 17:1127–1139CrossRefGoogle Scholar
  24. Sarfaraj HM, Sheeba F, Saba A, Mohd SK (2012) Marine natural products: a lead for anti-cancer. Indian J Geo-Mar Sci 41(1):27–39Google Scholar
  25. Schmitz F, Bowden B, Toth S (1993) Antitumor and cytotoxic compounds from marine organisms. Mar Biotechnol 1:197–308Google Scholar
  26. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA: Cancer J Clin 66(1):7–30Google Scholar
  27. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz AF (2003) Kahalalide, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2(9):863–872PubMedGoogle Scholar
  28. Suarez-Jimenez GM, Burgos-Hernandez A, Ezquerra-Brauer JM (2012) Bioactive peptides and depsipeptides with anticancer potential: sources from marine animals. Mar Drugs 10:963–986CrossRefGoogle Scholar
  29. Subramani R, Aalbersberg W (2012) Marine actinomycetes: an ongoing source of novel bioactive metabolites. Microbiol Res 167:571–580CrossRefGoogle Scholar
  30. Tan LT, Sitachitta N, Gerwick WH (2003) Theguineamides, novel cyclic depsipeptides from a Papua New Guinea collection of the marine cyanobacteriumLyngbyamajuscule. J Nat Prod 66(6):764–771CrossRefGoogle Scholar
  31. Thundimadathil J (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 967347:1–13CrossRefGoogle Scholar
  32. Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev 25(1):16–27CrossRefGoogle Scholar
  33. Ujiki MB, Milam B, Ding XZ, Roginsky AB, Salabat MR, Talamonti MS, Bell RH, Gu W, Silverman RB, Adrian TE (2006) A novel peptide sansalvamideanologue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Commun 340:1224–1228CrossRefGoogle Scholar
  34. Wesson KJ, Hamann MT, Keenamide A (1996) A bioactive cyclic peptide from the marine mollusk Pleurobranchus forskalii. J Nat Prod 59(6):629–631CrossRefGoogle Scholar
  35. Wiener L, Weaver MS, Bell CJ, Sansom-Daly UM (2015) Threading the cloak: palliative care education for care providers of adolescents and young adults with cancer. Clin Oncol Adolesc Young Adults 5:1–18PubMedPubMedCentralGoogle Scholar
  36. Yokokawa F, Sameshima H, Katagiri D, Aoyama T, Shioiri T (2002) Total syntheses of lyngbyabellin A and B, potent cytotoxic lipopeptides from the marine cyanobacterium Lyngbyamajuscule. Tetrahedron 58:9445–9458CrossRefGoogle Scholar
  37. Zheng LH, Wang YJ, Sheng J, Wang F, Zheng Y, Lin XK, Sun M (2011) Antitumor peptides from marine organisms. Mar Drugs 9:1840–1859CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Saravanan Ramachandran
    • 1
  • Senthilkumar Rajagopal
    • 2
  1. 1.Native Medicine and Marine Pharmacology Laboratory, Faculty of Allied Health SciencesChettinad Hospital and Research Institute, Chettinad Academy of Research and Education (Deemed to be a University)KelambakkamIndia
  2. 2.Department of BiochemistryRayalaseema UniversityKurnoolIndia

Personalised recommendations